Accessibility Menu
Lite Strategy logo

Lite Strategy(NASDAQ) MEIP

Current PriceN/A
Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-100%
5 Year-98%
1 Year-85%
1 Month+13%
Lite Strategy last closing stock price
MetricPriceDate
Last closeUSD 0.992026-07-24
Lite Strategy stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.18%USD 0.992026-07-17
1 month+13.22%USD 0.872026-06-24
3 month-16.24%USD 1.182026-04-24
Year to date-25.12%USD 1.322025-12-31
1 year-85.02%USD 6.602025-07-24
3 year-82.4%USD 5.622023-07-25
5 year-97.54%USD 40.242021-07-23
Since inception-99.99%USD 6,991.072003-12-18

Lite Strategy Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.20M

Net Income (TTM)

-$60.82M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

May 13, 2026

MEIP News

GettyImages-874899136

Why MEI Pharma Is Tanking 15.3% Today

Todd CampbellJul 2, 2020

7 Surprising 1-Star Stocks

Matt KoppenhefferJan 16, 2007

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lite Strategy

MEI Pharma, Inc. is a pharmaceutical company specializing in the development of novel cancer therapies. Based in the U.S. and listed on Nasdaq (MEIP), the company's primary strategy involves acquiring promising oncology agents and enhancing their value through clinical development and partnerships.

Products and Services

Voruciclib: An oral cyclin-dependent kinase 9 (CDK9) inhibitor previously in Phase 1 trials for acute myeloid leukemia.

ME-344: An intravenous inhibitor targeting mitochondrial oxidative phosphorylation for cancer treatment, currently in Phase 1b trials.

What Makes MEI Pharma, Inc. Special

MEI Pharma distinguishes itself with a specialized focus on targeted cancer therapies that address specific treatment gaps and resistance mechanisms. The company’s collaboration strategy enhances its resource capacity and opportunities for drug development.

Five Things You Need to Know

MEI Pharma is evaluating strategic alternatives, including potential transactions or a wind down of operations, to maximize value for shareholders.

The company has ceased development of voruciclib but continues nonclinical activities for its drug candidates.

MEI Pharma entered a Cooperation Agreement with Anson Funds and Cable Car Capital to return capital to shareholders.

A proposed merger with Infinity Pharmaceuticals was terminated in 2023 due to lack of stockholder approval.

The company has experienced leadership changes, with Justin J. File appointed as Acting CEO, following the resignation of key executives.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

4

CEO

Justin Jay File

Website

litestrategy.com

Headquarters

San Diego, CA 92130, US

MEIP Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-90.81%

Return on Capital

-103.09%

Return on Assets

-105.24%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$598.00K

Operating Income

-$58.09M

EBITDA

-$57.99M

Operating Cash Flow

-$10.42M

Capital Expenditure

$0.00

Free Cash Flow

-$10.42M

Cash & ST Invst.

$7.54M

Total Debt

$0.00

Lite Strategy Performance Analysis

Lite Strategy annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 40,697,000N/A
20232023-06-30USD 48,816,00019.9%
20242024-06-30USD 65,297,00033.8%
20252025-06-30USD 0N/A
Lite Strategy sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-30N/A
Q12025-09-30-100.0%
Q22025-12-31N/A
Q32026-03-31N/A
Lite Strategy annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD -9.99N/A
20232023-06-30USD -4.78-52.2%
20242024-06-30USD 2.67N/A
20252025-06-30USD -2.39N/A
Lite Strategy sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-06-30-2.6%
Q12025-09-3070.0%
Q22025-12-31-583.3%
Q32026-03-3119.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

28

N/A

Net Income

-$23.69M

-820.9%

EBITDA

-$21.61M

-679.0%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

$7.54M

-63.1%

Total Debt

$0.00

N/A

Accounts Receivable

$7.90M

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.05%

N/A

Return on Invested Capital

-22.40%

N/A

Free Cash Flow

-$1.52M

+53.5%

Operating Cash Flow

-$1.52M

+53.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MTVAMetaVia Inc.
$1.45-2.36%
TRAWTraws Pharma, Inc.
$0.49+0.96%
ELEVElevation Oncology, Inc.
$0.37-2.12%
PIRSPieris Pharmaceuticals, Inc.
$13.60-15.58%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.23+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.22-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$62.79-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$45.62+0.02%

Questions About MEIP

What is the current price of Lite Strategy?

Lite Strategy is trading at N/A per share.

What is the 52-week range for Lite Strategy?

Over the past 52 weeks, Lite Strategy has traded between N/A and N/A.

How much debt does Lite Strategy have?

As of the most recent reporting period, Lite Strategy reported total debt of $0.00.

How much cash does Lite Strategy have on hand?

Lite Strategy reported $7.54M in cash and cash equivalents in its most recent financial results.

What is Lite Strategy’s dividend yield?

Lite Strategy does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services